1. Generics Bulletin
  2. >>Preview

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

What's Next Image
Norstella/Citeline

Sandoz is set to break new ground in May, introducing the first US biosimilars to Amgen’s denosumab brands, Prolia and Xgeva, via a patent-litigation settlement agreement with the originator.

On 31 May, Sandoz is expected to launch its Wyost (denosumab-bddz) and Jubbonti (denosumab-bddz) rivals to Amgen’s Xgeva and Prolia brands respectively, following a deal penned...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Preview

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

What’s Next? Five Things To Look Out For In April

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for April 2025.

What’s Next? Five Things To Look Out For In March

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for March 2025.

What’s Next? Five Things To Look Out For In February

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for February 2025.

More from Biosimilars

Alvotech And Advanz Add Three More In €160m EU Partnership Expansion

 
• By Dean Rudge

Fresh from filing a proposed biosimilar to Xolair (omalizumab) in the UK, Alvotech and Advanz have shaken hands on a further deal to expand their partnership.

Abiogen And mAbxience Join Forces In Italy

 
• By Dave Wallace

Spanish biosimilars developer mAbxience has struck a deal with Italy’s Abiogen covering an undisclosed biosimilar for the Italian market.

Teva Brings In European Trastuzumab With Prestige BioPharma Agreement

 
• By Dean Rudge

Teva will now market biosimilar Herceptin in both the US and Europe, after penning an agreement with Singaporean firm Prestige BioPharma for its Tuznue rival to the monoclonal antibody to treat HER2-positive breast cancer and HER2-positive metastatic stomach cancer.